Accéder au contenu
Merck

Passer à

PP69

β-Amyloid Peptide (1-42), Human

Synonyme(s) :

β-Amyloid Peptide (1-42), Human, DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA

Se connecter pour consulter les tarifs organisationnels et contractuels.

Sélectionner une taille de conditionnement

Changer de vue
Taille/RéférenceDisponibilitéPrix
0.25 mg
Vérifier la disponibilité des articles du panier
472,00 €

A propos de cet article

Formule empirique (notation de Hill) :
C203H312N56O59S
Poids moléculaire :
4513.05
NACRES:
NA.77
UNSPSC Code:
12352202

472,00 €


Vérifier la disponibilité des articles du panier

​
Demander une commande sur mesure
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aider


assay

≥95% (HPLC)

Quality Segment

form

lyophilized

does not contain

preservative

manufacturer/tradename

Calbiochem®

storage condition

OK to freeze, desiccated (hygroscopic)

dilution

(Substrate Cleavage Assays (30-100 μg/mL))

solubility

50 mM Tris-HCl, pH >9.0: ≤1 mg/mL

shipped in

ambient

storage temp.

−20°C

General description

Wild-type, human Aβ1-42 peptide. A number of mutations, identified in the gene encoding the β-amyloid precursor protein (βAPP), have been linked to early-onset Familial Alzheimer’s Disease. Mutations in the genes encoding presenilin 1 and presenilin 2 have also been shown to alter the processing of βAPP, resulting in increased extracellular concentration of β-amyloid peptide Aβ1-42(43) relative to Aβ1-40. Biophysical and biochemical experiments suggest that Aβ1-42(43) may serve as a catalyst for the aggregation and deposition of β-amyloid peptide (Aβ) leading to neurotoxic effects associated with senile plaque formation. Furthermore, antibodies recog-nizing Aβ1-42 revealed that the long form of the peptide is increased in presenilin and βAPP mutants, while other studies have used Aβ specific antibodies to prevent the in vitro fibrillar aggregation of Aβ. Amino acid sequence verified by amino acid analysis or sequencing. This product is supplied in a form that is not neurotoxic prior to a preincubation step. The appearance of toxicity has recently been shown to correlate to the extent of β sheet structure. Useful for neurotoxicity studies and substrate cleavage assays.

Immunogen

Human

Application

Substrate Cleavage Assays (30-100 μg/ml)

Physical form

Supplied as a chloride salt.

Preparation Note

Reconstitute just prior to use. Do not store following reconstitution, as aggregation may occur.

Other Notes



Citron, M., et al. 1997. Nature Med.3, 67.
Hardy, J. 1997. Trends in Neurosci.20, 154.
Solomon, B., et al. 1997. Proc. Natl. Acad. Sci. USA94, 4109.
Duff, K., et al. 1996. Nature 383, 710.
Iwatsubo, T., et al. 1994. Neuron13, 45.
Suzuki, N., et al. 1994. Science264, 133.
Simmons, L.K., et al. 1994. Mol. Pharmacol.45, 373.
H-Asp-Ala-Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr-Glu-Val-His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val-Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met-Val-Gly-Gly-Val-Val-Ile-Ala-OH
Synthetic peptide corresponding to amino acid residues 1 - 42 of the processed human β-amyloid peptide.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Toxicity: Standard Handling (A)

Comparer avec des articles similaires

Voir la comparaison complète

Montrer les différences

1 of 1

Cet article
SCP0038PC150
description

-

description

≥90% (HPLC)

description

liquid, Calbiochem®

assay

≥95% (HPLC)

assay

≥90% (HPLC)

assay

-

Quality Level

100

Quality Level

-

Quality Level

100

form

lyophilized

form

lyophilized

form

liquid

storage temp.

−20°C

storage temp.

−20°C

storage temp.

−20°C

storage condition

OK to freeze, desiccated (hygroscopic)

storage condition

protect from light

storage condition

avoid repeated freeze/thaw cycles, OK to freeze

shipped in

ambient

shipped in

-

shipped in

wet ice


Classe de stockage

11 - Combustible Solids

WGK

WGK 1

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable



Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents




Questions

1–2 sur 2 questions  
  1. Is it possible to freeze the reconstituted peptide in liquid nitrogen in aliquots and store it at -80 degrees Celsius for future use?

    1 réponse
    1. This product should not be frozen in liquid nitrogen or stored at -80 °C, even in aliquots, because the product note states: “Reconstitute just prior to use. Do not store following reconstitution, as aggregation may occur.”

      Utile ?

  2. What is the process of reconstitution for this peptide? Can it be reconsitituted in HFIP followed by dessication and then finally dissolved in DMSO?

    1 réponse
    1. To reconstitute this product dissolve the lyophilized peptide at 1 mg/ml in 50 mM Tris-HCl, pH ?9.0. Dilute the peptide to an appropriate concentration with calcium and magnesium-free phosphate buffered saline (PBS) and incubate at 37°C for 24-48 h prior to neurotoxicity studies. Suggested neurotoxic concentration is 30-100 µg/ml. Do not store following reconstitution, as aggregation may occur. No data is available for reconstitution in hexafluoroisopropanol (HFIP), dessication, or dissolving in dimethylsulfoxide (DMSO).

      Utile ?

Évaluations

Aucune valeur de notation

Filtres actifs